Peter Michael Moyle
Cited by
Cited by
Modern subunit vaccines: development, components, and research opportunities
PM Moyle, I Toth
ChemMedChem 8 (3), 360-376, 2013
Self-adjuvanting lipopeptide vaccines
PM Moyle, I Toth
Current medicinal chemistry 15 (5), 506-516, 2008
Mucosal immunisation: adjuvants and delivery systems
PM Moyle, RP McGeary, JT Blanchfield, I Toth
Current Drug Delivery 1 (4), 385-396, 2004
Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines
PM Moyle
Biotechnology advances 35 (3), 375-389, 2017
Soil bacterial diffusible and volatile organic compounds inhibit Phytophthora capsici and promote plant growth
SF Syed-Ab-Rahman, LC Carvalhais, ET Chua, FY Chung, PM Moyle, ...
Science of the Total Environment 692, 267-280, 2019
Glucagon‐like peptide‐1 (GLP‐1)‐based therapeutics: current status and future opportunities beyond type 2 diabetes
JY Cheang, PM Moyle
ChemMedChem 13 (7), 662-671, 2018
Structure–activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates
ABM Abdel-Aal, MR Batzloff, Y Fujita, N Barozzi, A Faria, P Simerska, ...
Journal of medicinal chemistry 51 (1), 167-172, 2008
Method for the synthesis of mono-ADP-ribose conjugated peptides
PM Moyle, TW Muir
Journal of the American Chemical Society 132 (45), 15878-15880, 2010
Modern lipid‐, carbohydrate‐, and peptide‐based delivery systems for peptide, vaccine, and gene products
P Simerska, PM Moyle, I Toth
Medicinal research reviews 31 (4), 520-547, 2011
Polymer–peptide hybrids as a highly immunogenic single-dose nanovaccine
AAH Ahmad Fuaad, Z Jia, M Zaman, J Hartas, ZM Ziora, IC Lin, PM Moyle, ...
Nanomedicine 9 (1), 35-43, 2014
An Experimental Group A Streptococcus Vaccine That Reduces Pharyngitis and Tonsillitis in a Nonhuman Primate Model
T Rivera-Hernandez, DG Carnathan, S Jones, AJ Cork, MR Davies, ...
MBio 10 (2), 10.1128/mbio. 00693-19, 2019
Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines
PM Moyle, W Dai, Y Zhang, MR Batzloff, MF Good, I Toth
Bioconjugate chemistry 25 (5), 965-978, 2014
Oral vaccine delivery-new strategies and technologies
P Simerska, PM Moyle, C Olive, I Toth
Current Drug Delivery 6 (4), 347-358, 2009
Differing efficacies of lead group A streptococcal vaccine candidates and full-length M protein in cutaneous and invasive disease models
T Rivera-Hernandez, M Pandey, A Henningham, J Cole, B Choudhury, ...
MBio 7 (3), 10.1128/mbio. 00618-16, 2016
Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines
PM Moyle, C Olive, MF Ho, M Pandey, J Dyer, A Suhrbier, Y Fujita, I Toth
Journal of medicinal chemistry 50 (19), 4721-4727, 2007
Glucagon-like peptide-1 receptor agonists and strategies to improve their efficiency
SE Alavi, PJ Cabot, PM Moyle
Molecular pharmaceutics 16 (6), 2278-2295, 2019
Bioconjugation approaches to producing subunit vaccines composed of protein or peptide antigens and covalently attached toll-like receptor ligands
Z Xu, PM Moyle
Bioconjugate chemistry 29 (3), 572-586, 2017
Group A Streptococcal vaccine candidate: contribution of epitope to size, antigen presenting cell interaction and immunogenicity
M Zaman, S Chandrudu, AK Giddam, J Reiman, M Skwarczynski, ...
Nanomedicine 9 (17), 2613-2624, 2014
Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation
PM Moyle, C Olive, MF Ho, MF Good, I Toth
Journal of Medicinal Chemistry 49 (21), 6364-6370, 2006
Endosome escape strategies for improving the efficacy of oligonucleotide delivery systems
Y Wan, PM Moyle, I Toth
Current medicinal chemistry 22 (29), 3326-3346, 2015
The system can't perform the operation now. Try again later.
Articles 1–20